Back to search

Article

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)

2022-05-27

Abstract excerpt

Circulating tumor DNA (ctDNA), the tumor-derived cell-free DNA fragments in the bloodstream carrying tumor-specific genetic and epigenetic alterations, represents an emerging novel tool for minimal residual disease (MRD) assessment in patients with resected colorectal cancer (CRC). For many decades, precise risk-stratification following curative-intent colorectal surgery has remained an enduring challenge. The cur...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d93e53b0-0860-53e7-8413-c9b216a1115c
DOI
10.20944/preprints202205.0368.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)DOI 10.20944/preprints202205.0368.v1
Minimal residual disease detection with circulating tumor DNA in colorectal cancer: current horizons and future perspectives in clinical applicationsSemantic proximity
Circulating tumor DNA in colorectal cancer: biology, methods and applicationsSemantic proximity
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assaySemantic proximity
Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy.Semantic proximity
Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.Semantic proximity
Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and predictionSemantic proximity
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerSemantic proximity
Risk stratification by minimal residual disease detection and ctDNA dynamics from personalised assays in stage II-III colorectal cancer in a UK multi-centre prospective study (TRACC Part B)Semantic proximity
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.Semantic proximity
Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNASemantic proximity
Ultrasensitive tumour‐agnostic non‐invasive detection of colorectal cancer recurrence using ctDNA methylationSemantic proximity
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancerSemantic proximity
Select a neighboring publication to make it the new centre.